Greenwich LifeSciences, Inc.
GLSI
$9.46
-$0.40-4.06%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 282.95% | 26.74% | -4.02% | -17.06% | 15.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 185.06% | 9.04% | 52.27% | 13.21% | -2.03% |
| Operating Income | -185.06% | -9.04% | -52.27% | -13.21% | 2.03% |
| Income Before Tax | -192.72% | -11.58% | -60.08% | -16.39% | 1.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -192.72% | -11.58% | -60.08% | -16.39% | 1.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -192.72% | -11.58% | -60.08% | -16.39% | 1.57% |
| EBIT | -185.06% | -9.04% | -52.27% | -13.21% | 2.03% |
| EBITDA | -185.12% | -9.04% | -52.30% | -13.22% | 2.03% |
| EPS Basic | -186.01% | -9.08% | -59.43% | -16.26% | 4.60% |
| Normalized Basic EPS | -186.08% | -9.11% | -59.34% | -16.25% | 4.64% |
| EPS Diluted | -186.01% | -9.08% | -59.43% | -16.26% | 4.60% |
| Normalized Diluted EPS | -186.08% | -9.11% | -59.34% | -16.25% | 4.64% |
| Average Basic Shares Outstanding | 2.33% | 2.29% | 0.46% | 0.09% | 3.18% |
| Average Diluted Shares Outstanding | 2.33% | 2.29% | 0.46% | 0.09% | 3.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |